NDAORALTABLET, FOR SUSPENSION
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Lamivudine/Zidovudine is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors (NRTIs) indicated for HIV-1 infection. This oral tablet/suspension formulation targets HIV by inhibiting viral reverse transcriptase, preventing viral replication. The combination leverages synergistic activity to improve treatment efficacy and adherence.
PRE_LAUNCH
Pre-launch status signals commercial opportunity for early-stage roles in market access, sales operations, and launch planning; team size likely to expand post-approval.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on this pre-launch product offers ground-floor opportunity to shape market entry and build sales infrastructure in a competitive segment. Career trajectory depends on successful regulatory approval and Cipla's commitment to market expansion.
Brand ManagerRegional Sales Manager
Worked on LAMIVUDINE; ZIDOVUDINE at Cipla? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.